e-SPACE Heart Failure 2021

Published: 07 December 2021

Views:
5675
Likes:
7

Views:
5675
Likes:
7
Share:

Now Playing
Part 1 | Session 1 of 9
Real-world data, Covid-19 & biomarkers
Lars H Lund, James L Januzzi

Up Next
45m 19s

Part 1 | Session 2 Meet-the-expert session – Patient profiling in HF: tailoring medical therapy (Supported by an educational grant funding from AstraZeneca)
1h 7m 2s

Part 1 | Session 3 The new HF guidelines: diagnostic & treatment algorithms
Justin Ezekowitz, Yury Lopatin, Marco Metra
1h 5m 20s

Part 1 | Session 4 State of the art management of chronic HF
44m 49s

Part 1 | Session 5 Satellite symposium – Tailoring treatment to optimise care in HFrEF: The role of SGLT2 inhibitors (A symposium sponsored by the Boehringer Ingelheim & Lilly Alliance)
1h 5m 53s

Part 1 | Session 6 Acute HF and the transition to ambulatory care
1h 4m 2s

Part 1 | Session 7 Update on advanced HF, assist devices and heart transplantation
21m 56s

Part 1 | Session 8 Satellite symposium – Neuromodulation for the management of patients with HFrEF: the present and the future (Supported by an educational grant from CVRx)
1h 6m 7s

Part 1 | Session 9 Difficult problems in HF

1h 7m 48s

Part 2 | Session 1 Co-morbidities in HF affecting QoL and hard outcomes (part 1)
45m 28s

Part 2 | Session 2 Meet-the-expert session – Balancing RAASi therapy and potassium (Supported by an educational grant funding from AstraZeneca)
1h 9m 18s

Part 2 | Session 3 Co-morbidities in HF affecting QoL and hard outcomes (part 2)
1h 6m

Part 2 | Session 4 Valvular heart disease in HF
42m 18s

Part 2 | Session 5 Satellite symposium – Management of heart failure with PRESERVED ejection fraction ‒ time to tackle the unmet need (A symposium organised by Charite Friends & Sponsors Trust, supported by the Boehringer Ingelheim & Lilly Alliance)
1h 4m 1s

Part 2 | Session 6 Real-world data, Covid-19 & biomarkers
1h 4m 13s

Part 2 | Session 7 The new HF guidelines: diagnostic & treatment algorithms
44m 53s

Part 2 | Session 8 Meet-the-expert session – Symptoms, function and quality of life In patients with HFpEF (Supported by an educational grant funding from AstraZeneca)
1h 5m 26s

Part 2 | Session 9 State of the art management of chronic HF

1h 7m 20s

Part 3 | Session 1 Acute HF and the transition to ambulatory care
36m 34s

Part 3 | Session 2 Meet-the-expert session – GUIDE-HF: main findings and implications in clinical practice (Supported by an unrestricted educational grant by Abbott)
1h 5m 20s

Part 3 | Session 3 Update on advanced HF, assist devices and heart transplantation
1h 4m 54s

Part 3 | Session 4 Difficult problems in HF
45m 38s

Part 3 | Session 5 Satellite symposium – Implementing heart failure guidelines – management of iron deficiency along the patient’s journey (Supported by an unrestricted educational grant from Vifor Pharma)
1h 6m 4s

Part 3 | Session 6 Co-morbidities in HF affecting QoL and hard outcomes (part 1)
52m 48s

Part 3 | Session 7 Co-morbidities in HF affecting QoL and hard outcomes (part 2)
52m 48s

Part 3 | Session 8 The need for global cascade guidelines: Key points in the HF guideline approach
58m 45s

Part 3 | Session 9 Valvular heart disease in HF

Average (ratings)

No ratings

Your rating

Overview

e-SPACE Heart Failure 2021 was the second edition of the annual global online conference on heart failure. Brining together leading experts from across the globe, the sessions were designed to provide insight and best demonstrate how leading experts are implementing the new heart failure guidelines into clinical practice. Discover the latest information on diagnosis and evidence-based management strategies from across the globe.

Heart failure is a major public health problem facing millions of patients worldwide. It represents an ever-increasing burden for healthcare systems, patients and healthcare professionals. Care for heart failure patients requires constant education and up-to-date information. The health outcomes of heart failure patients depend upon the implementation of best care approaches and evidence-based management strategies. e-SPACE Heart Failure 2021 strives to share the latest scientific information with the global medical community.

These on-demand recordings of the live virtual event (8 – 10 October 2021) comprise:

Expert opinion and discussions from +40 international heart failure experts
+10 sessions covering the latest HF scientific information and education
Meet the Expert sessions and Symposia

e-SPACE Heart Failure 2021 would like to thank the following partners:

More from this programme

Part 1

DAY 1

9 sessions
Real-world data, Covid-19 & biomarkers	Watch now
Meet-the-expert session – Patient profiling in HF: tailoring medical therapy (Supported by an educational grant funding from AstraZeneca)	Watch now
The new HF guidelines: diagnostic & treatment algorithms	Watch now
State of the art management of chronic HF	Watch now
Satellite symposium – Tailoring treatment to optimise care in HFrEF: The role of SGLT2 inhibitors (A symposium sponsored by the Boehringer Ingelheim & Lilly Alliance)	Watch now
Acute HF and the transition to ambulatory care	Watch now
Update on advanced HF, assist devices and heart transplantation	Watch now
Satellite symposium – Neuromodulation for the management of patients with HFrEF: the present and the future (Supported by an educational grant from CVRx)	Watch now
Difficult problems in HF	Watch now

Part 2

DAY 2

9 sessions
Co-morbidities in HF affecting QoL and hard outcomes (part 1)	Watch now
Meet-the-expert session – Balancing RAASi therapy and potassium (Supported by an educational grant funding from AstraZeneca)	Watch now
Co-morbidities in HF affecting QoL and hard outcomes (part 2)	Watch now
Valvular heart disease in HF	Watch now
Satellite symposium – Management of heart failure with PRESERVED ejection fraction ‒ time to tackle the unmet need (A symposium organised by Charite Friends & Sponsors Trust, supported by the Boehringer Ingelheim & Lilly Alliance)	Watch now
Real-world data, Covid-19 & biomarkers	Watch now
The new HF guidelines: diagnostic & treatment algorithms	Watch now
Meet-the-expert session – Symptoms, function and quality of life In patients with HFpEF (Supported by an educational grant funding from AstraZeneca)	Watch now
State of the art management of chronic HF	Watch now

Part 3

DAY 3

9 sessions
Acute HF and the transition to ambulatory care	Watch now
Meet-the-expert session – GUIDE-HF: main findings and implications in clinical practice (Supported by an unrestricted educational grant by Abbott)	Watch now
Update on advanced HF, assist devices and heart transplantation	Watch now
Difficult problems in HF	Watch now
Satellite symposium – Implementing heart failure guidelines – management of iron deficiency along the patient’s journey (Supported by an unrestricted educational grant from Vifor Pharma)	Watch now
Co-morbidities in HF affecting QoL and hard outcomes (part 1)	Watch now
Co-morbidities in HF affecting QoL and hard outcomes (part 2)	Watch now
The need for global cascade guidelines: Key points in the HF guideline approach	Watch now
Valvular heart disease in HF	Watch now

Faculty Biographies

Lars H Lund

Associate Professor and Senior Consultant

Dr Lund's expertise is in HF big data and registry-based comparative outcomes studies and pragmatic trials. He is active in programs to improve utilisation of existing evidence-based interventions in heart failure with reduced ejection fraction, as well as in novel interventions.

Dr Lars Lund is an Editorial Board member of Cardiac Failure Review.

View full profile

James L Januzzi

Director of the Cardiac Intensive Care Unit

Dr James L Januzzi, is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.

Dr Januzzi was the top-ranked graduate in his class at New York Medical College. He completed an internship and residency at Brigham and Women’s Hospital prior to performing a clinical and research fellowship in cardiovascular medicine at the Massachusetts General Hospital, where he also completed a fellowship in cardiac ultrasound.

He speaks widely on the topic of biomarker testing in heart disease and treatment of heart failure. He has served as the Cardiology Consultant to the Boston Red Sox since 2005.

View full profile